Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Primary Membranous Nephropathy (PMN) is one of the most common causes of nephrotic syndrome in adults. The Modified Ponticelli Regimen (MPR) has been the standard therapy for decades, but its toxicities—especially those associated with alkylating agents—limit widespread use. Recently, B-cell-targeted therapies such as Rituximab have emerged, offering more specific immunosuppression. Combination therapy with Rituximab, low-dose cyclophosphamide, and steroids (RCP) aims to maximize remission while minimizing toxicity. This study evaluates the comparative efficacy and safety of these two regimens.
This is an open label, prospective, parallel group longitudinal study. conducted in the Department of Nephrology of NRS medical college and hospital, Kolkata. All biopsy proven idiopathic membranous nephropathy patients were included and their detail history and clinical data were recorded including PLA2R estimation. One arm patients received modified ponticelli regimen in which Cyclical cyclophosphamide & steroid was given for 6 months. In other arm the 3-drug regimen 1. Rituximab was administered as two 1,000 mg intravenous (IV) doses separated by 2 weeks. Thereafter administered as one 1,000 mg IV dose every 4 months for 2 years with the aim of continuous B-cell depletion. B-cell depletion was defined as total CD19+CD20+ cell count < 5 cells/μL.2. Oral cyclophosphamide was administered at 2.5 mg/kg daily for 1 week, then 1.5 mg/kg daily for 7 weeks. The cyclophosphamide dose was adjusted for kidney function. The cyclophosphamide dosing was not allowed to exceed 150 mg daily for the first week and 100 mg daily thereafter. 3. Prednisone was continued upto 28 weak with rapid tapering 60,40,30,20,15.12.5,10,7.5,5,2.5 mg then stop . Glomerular filtration rate (GFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. all followed upto 24 months.
A total of 60 biopsy-proven IMN patients were randomized into two groups: MPR (n=30) and RCP (n=30). M:F was 3:1. Median age was 61.06 +/- 4.7 years. Clinical response, remission rates, renal function (eGFR), and adverse events were recorded and compared (MPR VS RCP) at 1,3,6,12 months. At 6 month 24 hour urine protein (2.21 vs 1.7 gm, p=0.65), serum albumin (3.3 6 vs 3.48 gm/dL , p= 0.67) , eGFR (72.31 vs 74.38 ml/min, p=0.46), PLA2R negativity (87.5% vs 93.75%, p=0.54 ), complete remission (62.5% vs 68.75, p=0.8). Side effects in terms of fever, hypertension, cusing syndrome was less in RCP group (6.25%).
The RCP regimen offers a highly effective and safe alternative to the Modified Ponticelli Regimen for the treatment of idiopathic membranous nephropathy. It provides rapid and sustained remission with fewer adverse events and better tolerability.
